Close Menu

NEW YORK – With COVID-19 vaccinations beginning this week in the US, the country is entering a new stage of the pandemic that could ultimately end in widespread suppression of the virus.

The implications of this development for the lab industry are not entirely clear, but after almost a year spent building out molecular capacities to meet SARS-CoV-2 test demand, the question of what to do with that capacity in a post-COVID-19 environment looms on the horizon.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.